Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Recursion Pharmaceuticals Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.41, while Recursion Pharmaceuticals Inc trades at $3.04 (market cap $1.53B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| JEPQ | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $6.79 |
52-Week Low | $53.77 | $2.84 |
Market Cap | — | $1.53B |
Enterprise Value | — | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $58.59, up 0.14% with a bearish technical signal from moving averages. The ETF focuses on Nasdaq-100 exposure with covered-call strategies, generating monthly income through dividends. Recent distributions include $0.64, $0.56, and $0.59 per share, highlighting its income-oriented approach. Technical indicators show neutral oscillators but overall bearish momentum with key support at $57.
The outlook remains cautious due to technical bearishness and capped upside from covered calls. Investment appeal centers on high distribution yields for income-focused investors, though performance may lag pure Nasdaq-100 ETFs during rallies. Risks include strategy underperformance in bull markets and dependency on options income sustainability.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
